Share
1,068 Posts.
lightbulb Created with Sketch. 18
clock Created with Sketch. 23/04/15
08:09
Share
Originally posted by nikki
↑
Well I am not looking at exact wordings of the fellow members posts, but the overall sentiment of the message.. the fact that there were 2 new CEO's at Teva and two R&D rationalisations in 2012 and 2014 and MSB's products were not shelved would imply some form of validation of technology.
Expand
I think you have covered the issues succinctly Nikki and what you have posted backs up my understanding of the situation. Revascor remains a significant play for Teva, even though the branded space seems to be more their forte. Obviously the generic threat to their MS drug, Copaxone, is spurring them on. I'm hearing that in their recruiting for the Phase III heart failure trials, Teva is recruiting high risk cases to pave the way for a fast track designation by the FDA. And why not?.... this disease costs patients billions annually and if they get Phase III approval, it has been estimated that it could be a $US4bn pa drug. I would not be surprised that if results are promising at the interim stage, Teva looked to partner with someone with a stronger cardiac franchise. My thoughts only.
(20min delay)